Koers CytoDyn Inc. Other OTC
Aandelen
CYDY
US23283M1018
Biotechnologie & Medisch Onderzoek
Omzet 2022 | 0,27 0,25 | Omzet 2023 | - | Marktkapitalisatie | 239 mln. 221 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -211 mln. -194 mln. | Nettowinst (verlies) 2023 | -79 mln. -72,81 mln. | EV/omzet 2022 | 989.524.989 x |
Nettoschuld 2022 | 32,57 mln. 30,01 mln. | Nettoschuld 2023 | 33,01 mln. 30,43 mln. | EV/omzet 2023 | - |
K/w-verhouding 2022 |
-1,02
x | K/w-verhouding 2023 |
-2,52
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 99,15% |
Recentste transcriptie over CytoDyn Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 65 | 17/11 | |
Mitchell Cohen
DFI | Director of Finance/CFO | 68 | 01/02 |
Scott Hansen
CTO | Chief Tech/Sci/R&D Officer | - | 03-05-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Stephen Simes
BRD | Director/Board Member | 72 | 13-10-22 |
Ryan Dunlap
BRD | Director/Board Member | 54 | 24-08-22 |
Karen Brunke
BRD | Director/Board Member | 72 | 01-04-22 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+7,80% | 115 mld. | |
+12,68% | 107 mld. | |
-13,33% | 22,31 mld. | |
-3,99% | 21,6 mld. | |
-6,37% | 18,23 mld. | |
-39,93% | 17,62 mld. | |
+6,57% | 14,26 mld. | |
+32,57% | 12,37 mld. | |
-28,58% | 8,28 mld. |